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Abstract
Myeloid cells play a pivotal role in regulating innate and adaptive immune responses. In inflammation, autoimmunity, and 
after transplantation, myeloid cells have contrasting roles: on the one hand they initiate the immune response, promoting acti-
vation and expansion of effector T-cells, and on the other, they counter-regulate inflammation, maintain tissue homeostasis, 
and promote tolerance. The latter activities are mediated by several myeloid cells including polymorphonuclear neutrophils, 
macrophages, myeloid-derived suppressor cells, and dendritic cells. Since these cells have been associated with immune 
suppression and tolerance, they will be further referred to as myeloid regulatory cells (MRCs). In recent years, MRCs have 
emerged as a therapeutic target or have been regarded as a potential cellular therapeutic product for tolerance induction. 
However, several open questions must be addressed to enable the therapeutic application of MRCs including: how do they 
function at the site of inflammation, how to best target these cells to modulate their activities, and how to isolate or to gener-
ate pure populations for adoptive cell therapies. In this review, we will give an overview of the current knowledge on MRCs 
in inflammation, autoimmunity, and transplantation. We will discuss current strategies to target MRCs and to exploit their 
tolerogenic potential as a cell-based therapy.
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CNS  Central nervous system
Dexa  Dexamethasone
EAE  Experimental autoimmune 
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EBI3  Epstein-Barr virus-induced gene 3
HO-1  Heme-oxygenase 1
IBD  Inflammatory bowel disease
M-MDSCs  Monocytic myeloid-derived suppressor 
cells
M1  Pro-inflammatory macrophages
M2  Anti-inflammatory macrophages
MRCs  Myeloid regulatory cells
Mregs  Regulatory macrophages
MS  Multiple sclerosis
NETs  Neutrophil extracellular traps
pDCs  Plasmacytoid dendritic cells
PMN  Polymorphonuclear neutrophils
PMN-MDSCs  Granulocytic myeloid-derived suppressor 
cells
RA  Rheumatoid arthritis
SLE  Systemic lupus erythematosus
T1D  Type 1 Diabetes
tolDCs  Tolerogenic dendritic cells
VitD3  Vitamin D3
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Introduction
Dysregulation of the immune system and uncontrolled 
inflammation contribute to disease pathology. Myeloid 
cells play a key role in this process: they initiate effective 
and controlled immune responses that protect the host. 
However, under certain circumstances, they contribute to 
the inflammatory process, exacerbating disease pathology. 
Alternatively, myeloid cells with regulatory properties can 
protect the host from uncontrolled inflammation that might 
be triggered by pathogens or self-antigens (Ags). These 
cells, referred to as myeloid regulatory cells (MRCs), have 
been described within all the major myeloid cell lineages: 
polymorphonuclear neutrophils (PMN), macrophages, 
and dendritic cells (DCs). Moreover, a particular sub-
set of MRCs, termed myeloid-derived suppressor cells 
(MDSCs) according to their regulatory activity, has been 
described. MRCs promote a tolerogenic microenvironment 
that sustains the generation of T-regulatory cells (Tregs), 
thereby, the induction of tolerance. The ability of MRCs 
to control immune responses and to promote tolerance has 
prompted an interest in exploiting them therapeutically 
to treat inflammation, autoimmunity, or to improve out-
comes in transplantation. Here, we present an overview 
of the role of different MRCs in inflammation, autoim-
munity (see “Myeloid regulatory cells in inflammation and 
autoimmunity”), and in organ transplantation (see “Mye-
loid regulatory cells in allo-reactive T-cell responses”). 
We include data from experimental disease models and 
patients, if available.
Myeloid regulatory cells in inflammation 
and autoimmunity
The inflammatory response is a self-limiting process, 
culminating in the complete resolution of inflammation 
and a rapid return to tissue homeostasis. Disruption of 
the tightly regulated mechanisms that control the resolu-
tion of inflammation can result in excessive and persistent 
immune activation, which may cause tissue damage and 
promote the onset of autoimmune disease. Originally, the 
resolution of inflammation was considered a passive pro-
cess. However, strong evidence is emerging that the reso-
lution of inflammation is an active process crucial for pre-
venting uncontrolled inflammation and collateral damage. 
Myeloid cells, including MRCs, are a key component of 
the regulatory response and it is imperative to understand 
the mechanisms underpinning their recruitment and acti-
vation. While the suppression inhibition of inflammation 
in a myeloid cell-dependent manner can be detrimental in 
cancer and chronic infections (covered/reviewed by Uman-
sky et al. and Dorhoi et al. in companion reviews in this 
“symposium-in-writing”), it plays a key role in modulat-
ing T-cell responses and promoting/maintaining tolerance.
In the following sections, we will discuss the role that 
different MRCs play in modulating inflammation and auto-
immunity both in experimental models and patients. We also 
review therapeutic approaches targeting MRCs or exploiting 
MRC-based cell therapy to restore tolerance.
Contribution of polymorphonuclear neutrophils 
to inflammation in autoimmunity
Neutrophils are the most abundant circulating leukocytes in 
humans and the first line of defense against pathogens. They 
are present in large numbers at sites of autoimmune damage, 
such as the Rheumatoid Arthritis (RA) synovium, psoriatic 
skin, or Systemic Lupus Erythematosus (SLE) affected sites, 
where they contribute to pathology [1]. A reduced frequency 
of neutrophils in experimental models can lead to different 
outcomes: in Type 1 diabetes (T1D), this attenuates disease 
development [2], whereas in Genista mice, it is associated 
with spontaneous lupus-like autoimmunity [3]. Lower levels 
of neutrophils are typically associated with reduced disease 
severity, suggesting that neutrophils participate in promoting 
inflammation and autoimmunity.
Autoimmune disorders often involve organs that are 
densely colonized by microbes and frequently exposed to 
pathogens, e.g., the gastrointestinal tract or skin. Neutro-
phils are recruited to these sites to fight infection, frequently 
being the first cells recruited, where they act as effector cells 
via phagocytosis of the pathogens, release of lytic enzymes, 
and production of reactive oxygen species and inflammatory 
mediators [1]. Neutrophils mediate tissue damage by expos-
ing autoAgs (e.g., in autoimmune vasculitis where neutro-
phils become the target of myeloperoxidase or proteinase 
three specific autoantibodies), or releasing autoAgs, primar-
ily when dying by apoptosis or through the formation of neu-
trophil extracellular traps (NETs) [4]. During inflammatory 
responses, neutrophils interact with natural killer (NK) cells, 
macrophages, plasmacytoid (p)DCs, T- and B-lymphocytes, 
or can home to secondary lymphoid organs, where they 
serve as antigen-presenting cells (APCs) [5], activate auto-
reactive T-cells [5], and promote B-cell differentiation [6]. 
In autoimmunity, the best characterized neutrophil cellular 
partners are pDCs, the main producers of IFN-α and induc-
ers of Th17-mediated inflammation [7]. IFN-α production by 
pDCs requires the formation of nucleic acid complexes with 
specific peptides/proteins (e.g., anti-microbial peptide LL37, 
or neutrophil elastase together with secretory leukocyte pro-
tease inhibitor), which activate intracellular Toll-like recep-
tors (TLRs). NETs and NET-like structures containing neu-
trophil DNA, peptides, and proteins, directly activate pDCs 
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to produce IFN-α [8]. Several lines of evidence indicate that 
the neutrophil/pDC axis is active in autoimmunity: in psori-
atic patients, pDCs are in close proximity to neutrophils and 
NETs [9]; in SLE patients, neutrophils by extruding oxidized 
DNA within NETs stimulate pDCs to produce IFN-α [10]; 
in experimental models of T1D, neutrophils and pDCs accu-
mulate within the pancreas, where they contribute to tissue 
inflammation and autoantibody production [2].
The abnormalities in neutrophil phenotype and function 
reported in autoimmune diseases indicate that these cells 
play an important role in promoting/maintaining aberrant 
immune responses and tissue damage. However, recent evi-
dence indicates that neutrophils with regulatory activity also 
exist and can act to suppress T-cell responses [11], opening 
up the possibility that regulatory neutrophils are involved 
in dampening/controlling inflammatory responses in auto-
immunity. Neutrophils display phenotypic and functional 
heterogeneity, exemplified in humans by their sub-classi-
fication into low-density and “conventional” polymorpho-
nuclear neutrophils (PMNs) [11]. In autoimmune disease, 
low-density neutrophils promote inflammation. However, 
under certain conditions, e.g., in cancer, low-density granu-
locytes are a major constituent of the immunosuppressive 
cell subset, termed PMN-MDSCs. However, some PMN-
MDSCs can pass through the gradient and contaminate the 
high-density fraction of cells that is generally enriched in 
conventional PMNs [12]. Thereby, to clarify the role neutro-
phils play in autoimmune inflammation or tissue homeosta-
sis, a more complete characterization of neutrophil diversity 
and plasticity is needed. New tools currently under develop-
ment to dissect neutrophil phenotype and function in vivo 
will address these questions in the near future (covered/
reviewed by Cassetta et al. and [13] in companion reviews 
in this “symposium-in-writing”).
Role of monocytes/macrophages to promote/
control inflammation in autoimmunity
Circulating monocytes and tissue-resident macrophages are 
key cells of the innate immune system involved in the patho-
genesis of inflammatory and autoimmune diseases. Mono-
cytes and macrophages display a variety of effector functions 
depending on the activation of specific signaling pathways 
and on their metabolic adaptation.
Monocytes are highly plastic and heterogeneous, and 
can be classified into distinct subsets, based on pheno-
type and function. Human monocytes are classified as 
follows:  CD14highCD16− ‘classical’ inflammatory mono-
cytes, the prevalent predominant subset of blood mono-
cytes,  CD14+CD16+ ‘intermediate’ monocytes, and 
 CD14lowCD16+ ‘non-classical’ monocytes [14]. While 
all monocyte subsets have phagocytic potential and 
secrete pro-inflammatory cytokines, the ‘intermediate’ 
 CD14+CD16+ cells and ‘non-classical’  CD14lowCD16+ cells 
display distinct gene expression profiles from ‘classical’ 
 CD14highCD16− monocytes. The majority of IL-10-produc-
ing cells are  CD14+CD16+ ‘intermediate’ monocytes and 
these cells are selectively expanded in different patholo-
gies. In contrast,  CD14lowCD16+ ‘non-classical’ monocytes 
have a reduced phagocytic capacity, produce low amounts 
of reactive oxygen species, and have the unique ability to 
patrol the endothelium for signs of damage and infection 
[14]. The classification of human monocytes resembles 
that proposed in mice, with ‘classical’ monocytes being 
 Ly6ChighCX3CR1lowCCR2highCD43low, ‘intermediate’ mono-
cytes being  Ly6ChighCD43high, and ‘non-classical’ mono-
cytes defined as  Ly6ClowCX3CR1highCCR2lowCD43high [14].
In recent years, the belief that adult tissue-resident mac-
rophages are replenished by monocytes from the bone mar-
row has been revised. New evidence has emerged indicat-
ing that these immune cells have an embryonic origin and 
are self-maintaining regardless of bone marrow contribu-
tion. This new paradigm increases the complexity of tissue 
macrophages, indicating that in addition to the phenotypic 
and functional heterogeneity, populations of macrophages 
with different ontology co-exist at steady state and during 
inflammation within tissue [15]. Despite their origin, tissue-
resident macrophages have been categorized into classically 
activated, or pro-inflammatory (M1 and murine  Ly6Chigh) 
and alternatively activated, or anti-inflammatory (M2 and 
murine  Ly6Clow) macrophages. M1 and murine  Ly6Chigh 
macrophages are linked to inflammation and autoimmune 
development, whereas M2 and murine  Ly6Clow macrophages 
are associated with fibrosis, allergies, and tumor progression 
(covered/reviewed by Umansky et al. in companion reviews 
in this “symposium-in-writing”).
The selective expansion of per ipheral blood 
 CD14+CD16+ monocytes correlates with disease severity in 
RA, Inflammatory Bowel Disease (IBD), and psoriasis [16]. 
A specific reduction of circulating  CD14+CD16− monocytes 
in favor of  CD14lowCD16+ monocytes has been observed 
in RA patients responding to therapy [17]. Conversely, 
activated monocytes are expanded in the synovial fluid of 
RA patients [18], in the inflamed mucosa of IBD patients 
[19], and in the central nervous system (CNS) of relapsing 
remitting Multiple Sclerosis (MS) patients [20]. The mas-
sive infiltration of activated  CD14highCD16− monocytes is 
a major source of cytokines that disrupts tissue homeosta-
sis by promoting conversion of resident M2 into M1 mac-
rophages (Fig. 1). The role of resident M2 macrophages in 
maintaining tissue integrity and limiting/resolving inflam-
mation is supported by several lines of evidence both in 
non-inflamed tissues and experimental models, in which 
M2 and murine  Ly6Clow macrophage depletion results in 
worsened disease [21]. Conversely, experimental models of 
intestinal inflammation and autoimmune encephalomyelitis 
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(EAE) showed that increased frequency of inflammatory 
 Ly6Chigh macrophages promotes and sustains tissue damage 
and aggravates disease symptoms [19, 22]. These examples 
underline that the balance between M1/M2 macrophages is 
important for controlling/resolving inflammation. In IBD 
patients responding to anti-TNFα therapy accumulation of 
anti-inflammatory M2 macrophages has indeed been associ-
ated with mucosal healing [23].
Overall, accumulation and/or persistence of inflamma-
tory monocytes/macrophages within the target organ leads 
to excessive inflammation and induction of pathogenic 
cells in autoimmunity. Moreover, the concomitant reduc-
tion/impairment of macrophages with immunomodulatory 
activity sustains inflammation and contributes to disease 
progression. From a therapeutic point of view, this observa-
tion implies that to suppress inflammation and restore tissue 
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Fig. 1  Myeloid regulatory cell contribution in tissue homeostasis and 
inflammation. Several subsets of myeloid regulatory cells (MRCs) 
are involved in preventing uncontrolled responses, in maintaining 
tissue homeostasis, and in promoting resolution of inflammation. 
Tissue homeostasis. Tissue-resident non-inflammatory M2 mac-
rophages, immature and specialized DC subsets (iDC/TolDC), and 
MDSCs promote tissue homeostasis via different mechanisms: (1) 
secretion of anti-inflammatory mediators, such as IL-10 and TGF-
β, and expression of IDO; (2) induction of T-regulatory cells, both 
 FOXP3+ Tregs and Tr1 cells; (3) generation of a non-inflammatory 
milieu that leads to the differentiation of migrating classical inflam-
matory  CD14highCD16− and not classical  CD14lowCD16+ mono-
cytes into anti-inflammatory M2 macrophages, which contribute to 
T-regulatory cell induction. Tissue inflammation. Upon tissue injury 
or pathogen entry, PMNs are recruited at the site of inflammation 
and, by secreting pro-inflammatory mediators, lead to the activation 
of plasmacytoid DC (pDCs), which consequently release IFN-α. The 
inflammatory milieu promotes the recruitment of classical inflam-
matory  CD14highCD16− monocytes to the site of inflammation and 
their differentiation into pro-inflammatory M1 macrophages, and the 
activation and maturation of DCs. These cells in turn promote Th1 
and Th17 cell responses via secretion of pro-inflammatory cytokines, 
such as IL-12 and IL-23. It still remains to be clarified whether 
MDSCs contribute to tissue inflammation
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homeostasis, the accumulation of anti-inflammatory mono-
cytes/macrophages in the target organ is critical. Moreover, 
strategies aimed at targeting factors driving the selective dif-
ferentiation of migrating monocytes into M2 macrophages 
or preventing the conversion of tissue-resident M2 into M1 
macrophages, as already reported in transplantation settings 
(see below), may be more effective than blocking the devel-
opment of inflammatory cells.
Impact of myeloid‑derived suppressor cells 
in autoimmunity
MDSCs are a heterogeneous population of myeloid cells 
with different maturation stages, and the capacity to sup-
press immune responses [24]. MDSCs accumulate in the 
blood, bone marrow, and secondary lymphoid organs of 
tumor-bearing mice and cancer patients, in whom circulat-
ing levels of MDSCs correlate with clinical stage and meta-
static burden [24]. In mice, MDSCs are broadly defined as 
 CD11b+Gr-1+ cells, although they comprise subsets known 
as granulocytic (PMN)-MDSC  (CD11b+Ly6G+Ly6Clow) and 
monocytic (M)-MDSC  (CD11b+Ly6G−Ly6Chigh) cells. Sim-
ilar to their murine counterpart, human MDSCs comprise 
two cell subtypes with either granulocyte or monocyte mor-
phology. Human PMN-MDSCs  (CD11b+CD14−CD15+ or 
 CD66b+) and M-MDSCs  (CD11b+CD14+HLA-DR−CD15−) 
are phenotypically overlapping with neutrophils and mono-
cytes, respectively. However, these cells are defined as 
MDSCs as they display immunosuppressive functions [25]. 
The lack of consensus on specific markers, which would 
allow precise MDSC identification, and their phenotypic het-
erogeneity have generated controversial results regarding the 
role of MDSC in autoimmune diseases.
In experimental models of autoimmunity, accumulation 
of PMN-MDSCs in lymphoid and target organs is associ-
ated with inhibition of T-cell proliferation and reduction of 
pro-inflammatory cytokine release [26, 27]. Expansion of 
PMN-MDSCs has been described in the synovial fluid of 
RA patients, where they contribute to limiting the expan-
sion of autoreactive T-cells [28], and in the peripheral blood 
of MS patients with active disease. Furthermore, they sup-
press the activation and ex vivo proliferation of autologous 
 CD4+ T-cells [27]. Moreover, the proportion of MDSCs, 
comprising both PMN-MDSC and M-MDSC, correlated 
with disease course in EAE: both MDSC subsets decrease 
significantly during the remitting phase, and MDSCs com-
pletely disappear during the chronic phase [29]. Overall, 
these examples indicate that MDSCs play an important 
role in limiting inflammation. However, MDSCs have also 
been associated with increased inflammatory responses in 
autoimmunity. Indeed, an accumulation of MDSCs with the 
ability to promote an inflammatory microenvironment and 
pathogenic Th17 cells has been described in target tissues 
in experimental models of RA, EAE, and SLE [24]. Moreo-
ver, an increased frequency of circulating M-MDSCs in RA 
patients and of circulating PMN-MDSCs and M-MDSCs in 
SLE patients has been correlated with Th17 responses and 
disease severity [24].
These discrepancies may be explained by the differ-
ent strategies and markers used to identify MDSCs. Only 
recently, suggestions on the standardization of gating strate-
gies and markers to be used to distinguish PMN-MDSCs and 
M-MDSCs have been proposed [25]. Importantly, one of the 
key characteristics allowing the classification of both PMN-
MDSCs and M-MDSCs is their suppressive activity [24, 25]. 
However, the lack of consensus on the suppressive assays to 
be used to assess MDSC regulatory activity, as discussed in 
[13], has limited their definitive classification to date. Thus, 
to draw conclusions regarding MDSC contribution in the 
suppression or induction of autoreactive immune responses, 
consensus on biomarkers to distinguish MDSCs from other 
myeloid cell types and to discriminate the different MDSC 
subsets, and standardized methods to define their suppres-
sive properties are warranted.
Role of dendritic cells in promoting/regulating 
autoreactive T‑cell responses
DCs are professional APCs specialized in the uptake, pro-
cessing, and presentation of Ags to T-cells. Conventional, 
e.g.  immunogenic DCs, are involved in the initiation of 
adaptive immune responses. However, in steady state, these 
conventional DCs or specialized subsets of DCs, termed 
tolerogenic (tol)DCs, control tissue homeostasis and induce/
maintain tolerance [30]. Aberrant activation of immunogenic 
DCs or defects in the function of tolDCs are involved in 
breaking self-tolerance in autoimmune disease [30].
Accumulation and activation of conventional DCs in 
target organs promote autoreactive T-cell activation, and 
contribute to local inflammation in autoimmunity [30]. 
Increased numbers of activated conventional DCs with the 
ability to stimulate autoreactive T-cells and to secrete pro-
inflammatory cytokines are evident in synovial fluid of RA 
patients, in the demyelinating regions of the CNS, in psori-
atic skin lesions, and in intestinal mucosa in IBD patients. 
These cells contribute to effector Th1 and Th17 cell activa-
tion and disease progression [30].
Tissue-resident conventional DCs, characterized by the 
expression of specific markers, such as langerin (CD207) 
in the skin (Langerhans cells) or  CD103+ DCs in the intes-
tinal mucosa, perform tolerogenic functions and maintain 
tissue homeostasis [30]. An additional subset of tolerogenic 
DCs, are DC-10, characterized by the expression of HLA-G 
and Ig-like transcript-4 (ILT4) and the ability to promote 
IL-10-mediated tolerance [31]. These cells are present in 
secondary lymphoid organs [32] and in human decidua 
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during pregnancy, where they participate in maintaining 
fetal–maternal tolerance [33].
The regulatory activity of DCs depends both on their 
immature state and expression of immune-modulatory 
factors [e.g., IL-10, TGF-β, indoleamine 2,3-dioxygenase 
(IDO), aryl-hydrocarbon receptor]. These features are con-
trolled and induced by several environmental signals and 
crosstalk with local immune cells that, as described above, 
are dysregulated in inflamed tissues (Fig. 1). Therefore, we 
can speculate that in autoimmunity a pro-inflammatory envi-
ronment in the target organ, enriched in immune effector 
cells, leads to an increased number of inflammatory DCs 
and a reduced frequency of tolDCs or to a breakdown in 
tolDC regulatory activities. TolDCs and immunogenic DCs 
express many overlapping cell-surface markers. Therefore, 
only functional analysis, e.g., cytokine profile, stimulatory 
or suppressive activity, can be used to fully define them. The 
identification of specific biomarkers and consensus on the 
assays to determine tolDC suppressive activity are critical 
to better define their role in different autoimmune diseases. 
This knowledge is required to enable the development of 
targeted interventions to promote tolDC differentiation, 
recruitment to sites of inflammation, and maintenance of 
their regulatory function.
Therapeutic intervention to restore tolerance 
in autoimmunity
Current therapies to treat autoimmunity are based on sys-
temic administration of immunosuppressive drugs. While 
often leading to the amelioration of symptoms, these drugs 
can have widespread side effects and, in many cases, do not 
promote durable disease remission. Alternatively, biological 
therapies consisting of antibodies targeting pro-inflamma-
tory cytokines and their receptors can dampen inflammation 
and may prevent myeloid cell hyperactivation. While effica-
cious, these treatments are expensive and long-term admin-
istration can result in loss of response and cumulative side 
effects. An innovative and challenging approach to control 
auto-reactive T-cells and restore tolerance in autoimmun-
ity is to boost the regulatory arm of the immune system by 
suppling ex vivo generated MRCs (i.e., MDSCs or tolDCs).
Adoptive transfer of ex vivo isolated or in vitro induced 
M-MDSCs or PMN-MDSCs in experimental models of RA 
and EAE ameliorated disease severity by reducing Th1 and 
Th17 immune responses [24]. Conversely, the therapeu-
tic potential of MDSCs in T1D remains an open question: 
while adoptive transfer of MDSCs cells improved glucose 
tolerance and insulin resistance [34], in vitro bone marrow 
(BM)-derived MDSCs cells failed to prevent autoimmunity 
in vivo [35]. Ag specificity is likely one of the factors con-
tributing to these discrepancies, since infusion of MDSCs 
conferred protection only in the presence of cognate Ag 
[36]. The translation of effective MDSC-based therapies 
into clinical application faces several hurdles: how in vitro 
induced MDSCs respond to different inflammatory media-
tors; whether inflammatory mediators may inhibit MDSCs 
activity in vivo; and, importantly, whether in vitro induced 
MDSCs can mature and differentiate into conventional DCs 
and M1 macrophages, thus acquiring the ability to present 
autoAgs and exacerbate disease.
Human tolDCs potentially suitable for cell-based 
therapies can be differentiated in vitro using a plethora 
of agents [37]. The first clinical trial, performed in T1D 
patients, demonstrated the safety of this tolDC-based cell 
therapy approach but with limited effects on the patients’ 
insulin requirements [38]. Monocyte-derived DCs cultured 
with a nuclear factor-kB (NF-kB) inhibitor, pulsed with 
citrullinated peptide Ags, and injected in RA patients sig-
nificantly reduced levels of activated effector T-cells and 
pro-inflammatory cytokines [39]. DCs differentiated in the 
presence of vitamin D3 and dexamethasone (VitD3/Dexa) 
injected into the knee joints of RA patients can stabilize dis-
ease symptoms [40]. VitD3/Dexa DCs were also safely intra-
peritoneally administered to Crohn’s disease patients with 
active disease, but no clear clinical benefit was observed 
[41]. A similar approach is currently being used to treat MS 
patients with active disease: VitD3 DCs will be administered 
in MS patients via intradermal injection close to cervical 
lymph nodes (ClinicalTrials.gov identifier: NCT02618902) 
or directly injected in cervical lymph nodes (TOLERVIT-
MS, ClinicalTrials.gov identifier: NCT02903537).
These completed and ongoing studies have demonstrated 
the safety of the cell-based approach and some clinical ben-
efit. However, several questions remain before tolDC-based 
cell therapies can be routinely used to treat or cure auto-
immune disease, including the route of administration, the 
maintenance of the tolerogenic cell properties in vivo, and 
the ability to stably present autoAgs to inhibit auto-reactive 
T-cells while promoting autoAg-specific Tregs, thus re-
establishing long-standing tolerance.
Myeloid regulatory cells in allo‑reactive 
T‑cell responses
Organ transplantation is the most efficient treatment to 
replace the loss of organ function in patients suffering from 
end-stage diseases. Graft rejection remains a major limita-
tion of organ transplantation. Myeloid cells are involved both 
in innate non-specific reactions and donor-specific adaptive 
responses during allograft rejection. Three pathways pro-
mote allo-specific T-cell activation after organ transplanta-
tion [42]. In the direct pathway, after transplantation, donor 
APCs, mainly DCs, migrate from the graft into recipient 
secondary lymphoid organs, where they present alloAgs to 
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host naive T-cells. These activated T-cells differentiate into 
effector T-cells, that migrate back to the graft, where they 
can mediate rejection (Fig. 2). In the indirect pathway, host 
T-cells are primed in the secondary lymphoid organs by host 
APCs that uptake alloAg derived from dying migrated donor 
DCs (Fig. 2) [43]. Finally, in the semi-direct pathway host 
APCs acquire intact allogeneic MHC-peptide complex from 
donor APCs by direct cell-to-cell contact or via exosomes, 
leading to host T-cell stimulation [44]. The direct and the 
indirect pathway are mainly involved in early acute and 
chronic graft rejection, respectively.
Current pharmacological approaches to prevent graft 
rejection rely on long-term and non-specific therapies 
that result in metabolic toxicity and other undesirable 
side effects, such as infection and cancer. Consequently, 
graft survival outcomes are suboptimal. Novel therapeu-
tic approaches that target adaptive immune responses are 
currently under clinical testing. These approaches include 
the use of costimulatory blockade, lymphodepletion, or 
in vivo induction of Tregs. While promising results have 
been obtained, transplantation tolerance, defined as a state 
of donor-specific unresponsiveness, remains elusive [45]. 
This underlines the need of developing alternative tolerance-
inducing protocols. In the present section, we discuss the 
role of different subtypes of MRCs in modulating allograft 
rejection in experimental models and in patients. Moreover, 
we discuss MRC-based cell therapy to prevent graft rejection 
and promote tolerance.
Role of regulatory macrophages in organ 
transplantation
Historically, transplant immunologists have attempted to 
develop tolerogenic protocols by targeting the adaptive 
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DCs (dDCs) migrate to the secondary lymphoid organs and activate 
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migrate back into the graft where they mediate rejection. Moreover, 
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the graft, classical inflammatory  CD14highCD16− monocytes are 
recruited from the circulation and differentiate into M1 macrophages 
that, by secreting pro-inflammatory mediators, contribute to the 
expansion of effector alloAg-specific T-cells. The limited number of 
T-regulatory cells (Tregs and Tr1 cells) present within the graft is 
not sufficient to control the massive infiltration of effector alloAg-
specific T-cells. Tolerance. The graft microenvironment enriched 
of anti-inflammatory mediators, including IL-10, TGF-β, and CSF-
1, leads to the differentiation of migrating classical inflammatory 
 CD14highCD16− monocytes into anti-inflammatory M2 macrophages, 
which promote alloAgs-specific T-regulatory (Treg and Tr1) cells. In 
addition, the recruitment and/or induction of immature and tolero-
genic DC subsets (iDC/TolDC) within the graft sustains the expan-
sion/induction of alloAgs-specific T-regulatory (Treg and Tr1) cells, 
leading to long-term transplantation tolerance
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immune response. However, macrophage accumulation 
in the transplanted organ has long been recognized as a 
feature of allograft rejection. Inflammatory macrophages 
indeed initiate the allo-response against the transplanted 
organ [46] and represent a major cell subset during organ 
rejection (Fig. 2). Recent evidence suggests that mac-
rophages are also important during the induction of trans-
plantation tolerance [36]. The presence of graft-infiltrating 
macrophages with immunosuppressive activity has been 
described in long term surviving transplant recipients and 
is associated with unresponsiveness to the transplanted 
organ [47] (Fig. 2). In mice, inflammatory graft-infiltrating 
macrophages are  Ly6Chigh [48], while suppressive mac-
rophages are  Ly6Clow [49]. Inflammatory monocytes are 
rapidly recruited within the graft, where they can differ-
entiate into either immunogenic  Ly6Chigh or tolerogenic 
 Ly6Clow macrophages, depending on the local environment 
(Fig. 2). The behavior of migrating inflammatory mono-
cytes observed in organ transplantation is similar to that 
reported in autoimmunity. In both conditions, the local 
microenvironment dictates the differentiation program of 
infiltrating monocytes: in inflamed tissues (organs early 
after transplantation or injured tissues) migrating mono-
cytes acquire an inflammatory phenotype and differentiate 
into M1 or immunogenic DCs, that in turn promote T-cell 
activation and tissue damage. In steady-state conditions 
(engrafted transplanted organs or healthy tissues) migrat-
ing monocytes differentiate into anti-inflammatory/tolero-
genic cells or M2 macrophages and contribute to tissue 
homeostasis and tolerance induction.
Therapeutic approaches preventing the accumulation of 
inflammatory monocytes/macrophages in the transplanted 
organs or improving their differentiation into suppressive 
cells have given promising results: selective depletion of 
inflammatory  Ly6ChighCCR2high monocytes prolonged 
normoglycemia after allogeneic islet transplantation in 
streptozotocin-induced diabetic mice [50]. Alternatively, 
tolerogenic treatment with costimulatory blockade allowed 
inflammatory  Ly6Chigh monocytes infiltrating the allograft, 
early after transplantation, to differentiate into suppressive 
 Ly6Clow macrophages through a CSF1-dependent mecha-
nism [49]. These pre-clinical experiments show that target-
ing either donor- or recipient-derived monocytes represents 
a promising therapeutic approach to promote long-term graft 
acceptance in organ transplantation. However, there are no 
pharmacological agents that target monocyte/macrophages 
in clinical use. We believe that future experiments should 
consider the clinical development of immunotherapies that 
target myeloid cells within transplanted organs. One exam-
ple is the potential use of drug-loaded nanoparticles [51]. 
The identification of new markers that allow specific tar-
geting of myeloid cell subsets are required to facilitate the 
development of such innovative approaches.
Contribution of dendritic cells in promoting/
maintaining tolerance towards allo‑antigens
As discussed above, tolDCs are essential for tolerance in 
autoimmunity, and recent evidence indicates that they also 
promote tolerance in the setting of transplantation (Fig. 2). 
TolDCs prevent pathogenic responses using a large arsenal 
of mechanisms: they promote T-cell anergy, clonal deletion, 
and apoptosis; they express and secrete immunomodulatory 
mediators that generate a pro-tolerogenic microenvironment 
that supports T-cell unresponsiveness and induction of Tregs 
(as reviewed in [52]) (Fig. 2). TolDCs generated with low 
doses of GM-CSF express heme-oxygenase 1 (HO-1), whose 
engagement prevents allogenic T-cell proliferation [53] and 
expression of Epstein-Barr virus-induced gene 3 (EBI3), a 
member of the IL-12 family [54]. Cardiac allograft survival 
induced by tolDC immunotherapy is abrogated by specific 
inhibition of HO-1 [55] or anti-EBI3 treatment [54]. These 
examples demonstrate that tolDCs generated with low doses 
of GM-CSF modulate T-cell responses and promote allo-
graft tolerance via several mechanisms.
The transplantation procedure promotes a pro-inflam-
matory environment similar to that observed in the target 
organs of autoimmunity. In both instances, a hostile environ-
ment contributes to a reduction of the frequency of tolDCs 
and impairment of their immunosuppressive function. How-
ever, in contrast to most autoimmune settings, inflamma-
tion after organ transplantation is kept under control by the 
administration of immunosuppressive drugs that prevent 
immunogenic DC activation and consequently allo-reactive 
T-cell induction and function. Of note, these medications 
may also impair the induction and activity of tolDCs. Thus, 
the development of immunomodulatory agents that prevent 
inflammatory cell activation while favoring tolDC induction 
and function is a research priority in the setting of transplan-
tation and autoimmune disease.
Cell‑based approaches to promote tolerance 
after allogeneic transplantation
The results obtained in experimental models of allo-
transplantation and in proof-of-principle clinical trials in 
autoimmune diseases have prompted investigators to apply 
MRC-based cell approaches in the prevention of organ 
rejection. Hutchinson et al. developed a CSF1-dependent 
human suppressive myeloid cell-based medicinal product, 
called regulatory macrophages (Mregs) [56] and dem-
onstrated the feasibility and safety of Mreg administra-
tion in a proof-of-principle clinical trial in living-donor 
renal transplant recipients [56]. A clinical-grade proto-
col for the manufacturing of Mregs has been optimized 
and donor-derived Mregs are currently pre-operatively 
administered to living-donor kidney transplant recipients 
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under the umbrella of the ONE study (Clinicaltrials.
gov: NCT02085629). The ONE study consortium (http://
www.onest udy.org) is a European initiative of the FP7 7th 
Framework Programme ofthe European Union that aims 
at developing and comparing the safety and efficacy of 
various immunoregulatory cell products, including Mregs 
and tolDCs, as cell-based therapy in organ transplantation.
TolDCs suitable for cell-based therapy in transplanta-
tion can be generated by culturing precursors with several 
molecules including IL-10, TGF-β, VitD3, low dose of 
GM-CSF, rapamycin, tacrolimus or Dexa, or by down-
regulating costimulatory molecules (“Therapeutic inter-
vention to restore tolerance in autoimmunity”). Regardless 
of the treatment, differentiated tolDCs express low levels 
of MHC-II and costimulatory molecules, are refractory to 
maturation, induce allogenic T-cell hypo-responsiveness in 
a mixed lymphocyte reaction, produce immunomodulatory 
mediators, and support Treg differentiation and prolifera-
tion [57].
The seminal study that led to the use of tolDCs as cell 
therapy in the field of transplantation stemmed from data 
demonstrating that adoptive transfer of donor-derived 
tolDCs prolonged heart graft survival in mice [58]. Since 
then, several studies in pre-clinical models of transplanta-
tion confirmed the immunosuppressive capacity of tolDCs, 
and, more recently, a meta-analysis showed the effective-
ness of tolDCs in prolonging allograft survival [59]. Inter-
estingly, donor-derived tolDCs, alone or in combination 
with immunosuppressive drugs, prolong cardiac allograft 
survival [52], but it was shown that recipient-derived 
tolDCs have a superior activity [60]. Adoptive transfer of 
tolDCs generated with VitD3 and IL-10 prolonged kidney 
allograft survival in a clinically relevant rhesus macaque 
model [61]. More recently, Cuturi et al. performed a proof-
of-principle clinical trial with tolDCs generated in the 
presence of a low dose of GM-CSF as immunotherapy 
in kidney transplantation under the umbrella of the ONE 
study (Clinicaltrials.gov: NCT02252055).
The feasibility of generating ex vivo tolDCs for cell-
based approaches has now been proven. However, the 
presence of inflammation generated by the transplant 
procedure and the use of immunosuppressive drugs may 
hinder the tolerogenic effects of tolDCs [52]. One way to 
counter this possibility is to inject semi-mature tolDCs, 
that are more resistant to this inflammatory environment 
and have been demonstrated to be effective in prolonging 
organ graft survival [52]. Furthermore, pre-clinical studies 
demonstrated that co-administration of immunosuppres-
sive drugs in combination with tolDCs did not impair their 
activity (reviewed in [52]). The selection of the optimum 
immunosuppressive regimen that can sustain tolerance is 
an important consideration for the clinical application of 
tolDC-based therapy to prevent graft rejection.
Conclusions and perspectives
Myeloid cells play a pivotal role in regulating innate and 
adaptive immune responses. They have a dual purpose, 
they can initiate effective controlled inflammation leading 
to activation of appropriate protective immune responses 
and they are involved in the resolution of inflammation and 
the promotion of tissue homeostasis and tolerance. Failure 
in either capacity has important consequences potentially 
leading to pathology. The discovery that several subtypes 
of myeloid cells with regulatory activity (MRCs) exist 
in vivo and can be induced in vitro opens the prospect of 
clinical interventions designed to induce/modulate these 
cells in vivo and use them as tolerogenic tool to re-estab-
lish/promote tolerance in autoimmune diseases and after 
transplantation. Recently, tolDC- and Mreg-based cell 
therapies have entered the clinical arena demonstrating 
the feasibility and safety of the approach. These encourag-
ing results support the potential of using other subtypes 
of MRCs as a tolerogenic cell therapy in clinical practice.
A number of open questions remain regarding MRCs 
and their contribution to autoimmunity and transplanta-
tion: the most important is the identification of the relative 
contribution of each MRC subset in different pathological 
settings. The lack of consensus on markers to identify each 
MRC subset not only makes their identification in patients 
difficult, but also hampers the ability to specifically target 
the optimum cell type. In 2014, a European network (Mye-
EUNITER, http://www.mye-eunit er.eu/) was initiated 
under the umbrella of COST (European cooperation in 
science and technology) with the aim of joining forces to 
standardize the phenotypical and functional characteriza-
tion of MRCs with the overall objective of expediting the 
application of this knowledge in diagnosis and treatment 
of a broad spectrum of disease. This is the first European 
initiative bringing together MRC experts from different 
research domains: basic, translational and clinical. By 
creating a forum for knowledge and expertise exchange, 
Mye-EUNITER will standardize tools to improve MRCs 
identification and characterization of their role in healthy 
and pathological conditions. This effort will contribute to 
increasing our knowledge about these particular subsets of 
myeloid cells and to identify strategies to target them at 
best or to use them as a cell-based product.
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